Upjohn Co. said its profit rose 20%...

Upjohn Co. said its profit rose 20% in the third quarter to $89.6 million, largely attributable to sales of its baldness medication Rogaine. The Kalamazoo, Mich.-based pharmaceutical products firm did not give specific sales figures, but said Rogaine led major products in foreign sales growth and received new marketing approvals during the quarter in several countries.